RT @brendonneuen: @RahulDBarmanray @VladoPerkovic @WhitGP Completely agree with Vlado. In clinic, I am initiating for CV/renal protection i…
@RahulDBarmanray @VladoPerkovic @WhitGP Completely agree with Vlado. In clinic, I am initiating for CV/renal protection if GFR>30 and albuminuria, not for glycemic control. Here is my list of things to do in practice (from https://t.co/V4qN4fJlpu) https
RT @jardine_meg: Patient education always key. Worth getting right for SGLT2is: reduce dialysis/transplant by 33%, heart failure by 32%, C…
RT @jardine_meg: Patient education always key. Worth getting right for SGLT2is: reduce dialysis/transplant by 33%, heart failure by 32%, C…
RT @jardine_meg: Patient education always key. Worth getting right for SGLT2is: reduce dialysis/transplant by 33%, heart failure by 32%, C…
RT @jardine_meg: Patient education always key. Worth getting right for SGLT2is: reduce dialysis/transplant by 33%, heart failure by 32%, C…
RT @jardine_meg: Patient education always key. Worth getting right for SGLT2is: reduce dialysis/transplant by 33%, heart failure by 32%, C…
RT @jardine_meg: Patient education always key. Worth getting right for SGLT2is: reduce dialysis/transplant by 33%, heart failure by 32%, C…
RT @jardine_meg: Patient education always key. Worth getting right for SGLT2is: reduce dialysis/transplant by 33%, heart failure by 32%, C…
RT @jardine_meg: Patient education always key. Worth getting right for SGLT2is: reduce dialysis/transplant by 33%, heart failure by 32%, C…
RT @jardine_meg: Patient education always key. Worth getting right for SGLT2is: reduce dialysis/transplant by 33%, heart failure by 32%, C…
RT @jardine_meg: Patient education always key. Worth getting right for SGLT2is: reduce dialysis/transplant by 33%, heart failure by 32%, C…
Patient education always key. Worth getting right for SGLT2is: reduce dialysis/transplant by 33%, heart failure by 32%, CKD prog. by 42%, AKI by 25%, mortality by 15% Brief tips for clinical practice here https://t.co/8XJcP0SgiI Brainstrust: What material
RT @RevistaMFSamfyc: Inhibidores del cotransportador sodio-glucosa en la diabetes tipo 2: pensar más allá del descenso de glucosa https://t…
Inhibidores del cotransportador sodio-glucosa en la diabetes tipo 2: pensar más allá del descenso de glucosa https://t.co/FcwVSxz8cT PMID 31615819
(CMAJ) ISGLT2 en pac con DM2 https://t.co/1NZS8w0Vqu Más allá del control glucémico
Recognized adverse events with SGLT2 inhibitors include mycotic genital infections, volume depletion.Clinicians should be aware of other potentially serious adverse effects, particularly diabetic ketoacidosis and possibly amputations https://t.co/oXzK8Qwh7
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @aishaikh: Link for the articles ⚡️PLA2R Ab in Lupus 👉🏽 https://t.co/v5xi0WkXW7 ⚡️Relowering of Plasma Na 👉🏽 https://t.co/YoAWc84Yet ⚡️…
RT @aishaikh: Link for the articles ⚡️PLA2R Ab in Lupus 👉🏽 https://t.co/v5xi0WkXW7 ⚡️Relowering of Plasma Na 👉🏽 https://t.co/YoAWc84Yet ⚡️…
RT @aishaikh: Link for the articles ⚡️PLA2R Ab in Lupus 👉🏽 https://t.co/v5xi0WkXW7 ⚡️Relowering of Plasma Na 👉🏽 https://t.co/YoAWc84Yet ⚡️…
Good papers indeed
Link for the articles ⚡️PLA2R Ab in Lupus 👉🏽 https://t.co/v5xi0WkXW7 ⚡️Relowering of Plasma Na 👉🏽 https://t.co/YoAWc84Yet ⚡️Acute Tubular Injury 👉🏽 https://t.co/uet973Us9t ⚡️SGLT2 inh: beyond glucose lowering 👉🏽 https://t.co/seAyWHyQjo
RT @CMAJ: SGLT2 inhibitors are now often used to treat type 2 diabetes but bear in mind rare serious adverse effects. Read the full review:…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @CMAJ: SGLT2 inhibitors are now often used to treat type 2 diabetes but bear in mind rare serious adverse effects. Read the full review:…
RT @CMAJ: SGLT2 inhibitors are now often used to treat type 2 diabetes but bear in mind rare serious adverse effects. Read the full review:…
RT @CMAJ: SGLT2 inhibitors are now often used to treat type 2 diabetes but bear in mind rare serious adverse effects. Read the full review:…
RT @CMAJ: SGLT2 inhibitors are now often used to treat type 2 diabetes but bear in mind rare serious adverse effects. Read the full review:…
SGLT2 inhibitors are now often used to treat type 2 diabetes but bear in mind rare serious adverse effects. Read the full review: https://t.co/g7LF9plicw @brendonneuen @jardine_meg @vladoperkovic @georgeinstitute https://t.co/glg1pdfiJe
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
Everything you should know about SGLT2 inhibitors (to date): https://t.co/crixArvcgC @CMAJ
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
RT @brendonneuen: Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGL…
Treatment recommendations for diabetes are changing more quickly than ever before. Find out more in our new review of SGLT2 inhibitors & diabetes guidelines, with contributions from David Cherney, @jardine_meg & @VladoPerkovic Free this week in @
Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering - CMAJ https://t.co/7wrYELua2N